Oppenheimer Asset Management Inc. Has $12.34 Million Stock Holdings in Stryker Co. (NYSE:SYK)

Oppenheimer Asset Management Inc. lowered its stake in Stryker Co. (NYSE:SYK) by 3.2% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 34,163 shares of the medical technology company’s stock after selling 1,119 shares during the quarter. Oppenheimer Asset Management Inc.’s holdings in Stryker were worth $12,342,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of the stock. Koshinski Asset Management Inc. bought a new stake in Stryker during the first quarter worth $795,000. Kingsview Wealth Management LLC raised its holdings in shares of Stryker by 0.3% in the 1st quarter. Kingsview Wealth Management LLC now owns 14,166 shares of the medical technology company’s stock valued at $5,069,000 after purchasing an additional 47 shares during the period. Lord Abbett & CO. LLC lifted its stake in Stryker by 5.0% in the 1st quarter. Lord Abbett & CO. LLC now owns 821 shares of the medical technology company’s stock valued at $294,000 after purchasing an additional 39 shares during the last quarter. Orion Portfolio Solutions LLC grew its holdings in Stryker by 10.7% during the first quarter. Orion Portfolio Solutions LLC now owns 14,202 shares of the medical technology company’s stock worth $5,082,000 after purchasing an additional 1,372 shares during the period. Finally, Great Lakes Retirement Inc. increased its position in Stryker by 1.9% during the first quarter. Great Lakes Retirement Inc. now owns 4,250 shares of the medical technology company’s stock worth $1,521,000 after buying an additional 78 shares during the last quarter. 77.09% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, CEO Kevin Lobo sold 57,313 shares of the company’s stock in a transaction that occurred on Thursday, November 7th. The stock was sold at an average price of $368.70, for a total value of $21,131,303.10. Following the sale, the chief executive officer now directly owns 100,027 shares in the company, valued at $36,879,954.90. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other news, CEO Kevin Lobo sold 57,313 shares of Stryker stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $368.70, for a total value of $21,131,303.10. Following the completion of the transaction, the chief executive officer now directly owns 100,027 shares of the company’s stock, valued at approximately $36,879,954.90. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Viju Menon sold 600 shares of the firm’s stock in a transaction that occurred on Tuesday, August 27th. The stock was sold at an average price of $355.00, for a total value of $213,000.00. Following the sale, the insider now directly owns 9,069 shares of the company’s stock, valued at $3,219,495. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 67,381 shares of company stock valued at $24,825,275. Company insiders own 5.90% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have recently commented on the company. Wells Fargo & Company lifted their target price on Stryker from $381.00 to $405.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 30th. Stifel Nicolaus reduced their price objective on shares of Stryker from $375.00 to $365.00 and set a “buy” rating for the company in a research report on Wednesday, July 31st. Royal Bank of Canada increased their price objective on shares of Stryker from $386.00 to $400.00 and gave the company an “outperform” rating in a research report on Wednesday, October 30th. StockNews.com upgraded shares of Stryker from a “hold” rating to a “buy” rating in a research note on Thursday. Finally, JPMorgan Chase & Co. raised their price objective on shares of Stryker from $375.00 to $420.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 30th. Four research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $393.65.

Stryker Price Performance

Stryker stock opened at $388.34 on Thursday. The company has a market capitalization of $148.04 billion, a PE ratio of 41.62, a P/E/G ratio of 2.92 and a beta of 0.91. The company has a current ratio of 1.91, a quick ratio of 1.22 and a debt-to-equity ratio of 0.66. The stock has a 50-day moving average price of $362.38 and a two-hundred day moving average price of $346.42. Stryker Co. has a 12 month low of $282.35 and a 12 month high of $390.59.

Stryker (NYSE:SYK) last announced its quarterly earnings results on Tuesday, October 29th. The medical technology company reported $2.87 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.77 by $0.10. The firm had revenue of $5.49 billion during the quarter, compared to analysts’ expectations of $5.37 billion. Stryker had a net margin of 16.34% and a return on equity of 23.07%. The company’s revenue was up 11.9% on a year-over-year basis. During the same period in the prior year, the company posted $2.46 EPS. Analysts expect that Stryker Co. will post 12.06 EPS for the current year.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.